A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase δ (PI3Kδ), was evaluated in a 48-week phase 1 study (50-350 mg daily or twice daily) enrolling 40 patients with relapsed or refractory mantle cell lymphoma (MCL). Primary outcome was safety and dose-limiting toxicity (DLT). Secondary out...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood
मुख्य लेखकों: Kahl, Brad S., Spurgeon, Stephen E., Furman, Richard R., Flinn, Ian W., Coutre, Steven E., Brown, Jennifer R., Benson, Don M., Byrd, John C., Peterman, Sissy, Cho, Yoonjin, Yu, Albert, Godfrey, Wayne R., Wagner-Johnston, Nina D.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2014
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4260977/
https://ncbi.nlm.nih.gov/pubmed/24615778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-537555
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन